Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock
Pulse Biosciences, Inc. (NASDAQ:PLSE) shareholders (or potential shareholders) will be happy to see that the Executive Chairman, Robert Duggan, recently bought a whopping US$2.0m worth of stock, at a price of US$9.38. While that only increased their holding size by 0.6%, it is still a big swing by our standards.
Check out our latest analysis for Pulse Biosciences
Pulse Biosciences Insider Transactions Over The Last Year
In fact, the recent purchase by Executive Chairman Robert Duggan was not their only acquisition of Pulse Biosciences shares this year. Earlier in the year, they paid US$6.51 per share in a US$65m purchase. We do like to see buying, but this purchase was made at well below the current price of US$9.16. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months Pulse Biosciences insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Does Pulse Biosciences Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Pulse Biosciences insiders own 68% of the company, currently worth about US$341m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
What Might The Insider Transactions At Pulse Biosciences Tell Us?
It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Pulse Biosciences insiders are well aligned, and quite possibly think the share price is too low. That's what I like to see! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Pulse Biosciences. To help with this, we've discovered 4 warning signs (2 are potentially serious!) that you ought to be aware of before buying any shares in Pulse Biosciences.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
